Custom Knockout Cell Lines for Metabolic Pathways
The target menu
| Module | Common targets | Note |
|---|---|---|
| Glucose uptake and glycolysis | HK1, HK2, PKM, LDHA, PDK1 | HK1/HK2 and LDHA/LDHB require double knockouts |
| Lactate transport | SLC16A1 (MCT1), SLC16A3 (MCT4) | Single knockouts are often compensated |
| Pentose phosphate | G6PD, PGD | G6PD is X-linked; check the background karyotype |
| De novo lipogenesis | ACACB (ACC2), ACACA (ACC1), FASN, SCD | ACC1 and ACC2 are separate compartments, separate genes |
| Fatty acid oxidation | CPT1A, CPT2, ACADM, HADHA | CPT1A is the gate; CPT2 defects are a different model |
| Glutamine | GLS, GOT1, GLUD1 | GLS and GLS2 are separate genes with different expression |
| Serine and one-carbon | PHGDH, SHMT2, MTHFD2 | SHMT1 and SHMT2 are cytosolic and mitochondrial |
| OXPHOS | Nuclear-encoded complex subunits | mtDNA-encoded subunits need a different approach entirely |
Important distinction. ACC1 and ACC2 are not isoforms of one enzyme in the usual sense: they are separate genes, and ACC2 carries a mitochondrial targeting sequence whose product inhibits CPT1A locally. Knocking out one and describing the result as "ACC loss" mislabels the compartment.
Pairs that require a double knockout
| Pair | Why single knockout is usually silent | Expected double-knockout readout |
|---|---|---|
| HK1 / HK2 | Reciprocal expression between tissue types; one compensates | Glycolytic flux falls; growth may still continue on OXPHOS |
| LDHA / LDHB | Opposite direction, same reaction | Lactate production and consumption both affected |
| GLS / GLS2 | Different expression programmes, same activity | Glutamine-dependent growth reduced |
| SHMT1 / SHMT2 | Cytosolic and mitochondrial one-carbon pools | Serine-to-glycine flux and nucleotide synthesis |
| ACACA / ACACB | Cytosolic and mitochondrial malonyl-CoA | Lipogenesis and CPT1A gate separately affected |
| CPT1A / CPT1C | CPT1C is brain-enriched and has low activity | Usually CPT1A alone is the functional gate |
We will tell you before quoting whether your target falls in this table. A single-knockout project on a redundant pair is a project designed to produce a null result.
What we validate
| Level | Assay | Why it is part of delivery |
|---|---|---|
| Genotype | Junction PCR plus Sanger or amplicon sequencing of both alleles | Confirms the edit, and the zygosity |
| Protein | Immunoblot, with a validated antibody | A frameshift can produce a stable truncated fragment |
| Metabolite | The relevant pool, in the relevant compartment where possible | Confirms the pathway, not only the gene |
| Function | Flux or growth under restriction | Confirms the model is usable, not only edited |
The third and fourth levels are what separate a knockout line from an edited line. We deliver them because a client who receives only sequencing data will repeat the experiment in six months.
Caveat on antibodies. A large fraction of commercial antibodies against metabolic enzymes are not validated for the species or for knockout tissue. Where we cannot validate, we say so and use an orthogonal method rather than reporting an uninterpretable blot.
Turnaround
| Format | Working days |
|---|---|
| Single knockout, pool | 21–28 |
| Single knockout, two clones | 42–56 |
| Double knockout, two clones | 70–98 |
| Knockout plus rescue line | Add 28–35 |
Timelines assume a diploid, tractable background. Primary cells, iPSCs and near-triploid lines are quoted individually.
What we need from you
- Gene, transcript and isoform.
- Cell background, with authentication and mycoplasma status.
- Whether the claim needs a clone or a pool — they support different conclusions.
- Whether a rescue line is required, and whether a resistant cDNA exists.
What we do not promise
- • A phenotype. We deliver the edit and its validation. Whether the pathway matters is the experiment.
- • Editing efficiency at unvalidated loci. We screen guides and report the measured efficiency; we do not quote a number before screening.
- • That the clone has no adaptation. Clones selected over weeks change. We report doubling time and, on request, a metabolic baseline, so that adaptation is visible rather than hidden.
- • mtDNA-encoded targets. These require cybrid or mitochondrial replacement approaches, which we quote separately.
Where this connects
- • Glucose, lipid, amino acid and mitochondrial pillars supply the redundancy and compartment logic behind the target menu.
- • The self-assessment scores whether the perturbation resolves the node; a double knockout is often the difference between 1 and 3 on that row.
- • Tumour dependency work needs the genetic arm this page delivers before a compound-based claim is made.
Selected references for further reading
- • Abu-Elheiga L, et al. Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. PNAS. 2005;102:12011–12016.
- • Patra KC, et al. Hexokinase 2 is required for tumour initiation and maintenance. Cancer Cell. 2013;24:213–228.
- • Davidson SM, et al. Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metabolism. 2016;23:517–528.
- • Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. Cell Metabolism. 2017;25:27–42.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »